Search research articles
Contact Us
Filters
Showing results (51-60 of 130) with videos related to
Page
of 13
Sort By:
Blood
|
April 20, 2002
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
Michael S von Bergwelt-Baildon, Robert H Vonderheide, Britta Maecker, et al.
Cancers
|
December 23, 2023
The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies
Seth Kibel, Nathan Kuehne, Mauricio Fernando Ribeiro, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 27, 2022
Modification of the HLA-A*24:02 Peptide Binding Pocket Enhances Cognate Peptide-Binding Capacity and Antigen-Specific T Cell Activation
Kenji Murata, Dalam Ly, Hiroshi Saijo, et al.
Cell Reports. Medicine
|
March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
Juanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Cancers
|
September 9, 2023
Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre
Erica C Koch Hein, Maysa Vilbert, Ian Hirsch, et al.
Journal for Immunotherapy of Cancer
|
January 23, 2021
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
April A N Rose, Susan M Armstrong, David Hogg, et al.
Nature Communications
|
August 13, 2021
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2019
Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Jason J Luke, Daniel J Olson, Jacob B Allred, et al.
Nature Communications
|
December 8, 2020
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Richard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 130) with videos related to
Sort By:
Page
of 13
Blood
|
April 20, 2002
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
Michael S von Bergwelt-Baildon, Robert H Vonderheide, Britta Maecker, et al.
Cancers
|
December 23, 2023
The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies
Seth Kibel, Nathan Kuehne, Mauricio Fernando Ribeiro, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 27, 2022
Modification of the HLA-A*24:02 Peptide Binding Pocket Enhances Cognate Peptide-Binding Capacity and Antigen-Specific T Cell Activation
Kenji Murata, Dalam Ly, Hiroshi Saijo, et al.
Cell Reports. Medicine
|
March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
Juanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Cancers
|
September 9, 2023
Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre
Erica C Koch Hein, Maysa Vilbert, Ian Hirsch, et al.
Journal for Immunotherapy of Cancer
|
January 23, 2021
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
April A N Rose, Susan M Armstrong, David Hogg, et al.
Nature Communications
|
August 13, 2021
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2019
Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Jason J Luke, Daniel J Olson, Jacob B Allred, et al.
Nature Communications
|
December 8, 2020
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Richard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
Page
of 13